Eli Lilly will acquire Engage BioLogics, a company developing nonviral DNA delivery technology, for 293 billion won ($202 million). The acquisition includes an upfront payment and milestone payments. Engage has a “Tethosome” platform that uses lipid nanoparticles (LNPs) and mRNA-
2026-05-21
Parabilis, which has raised 1.16 trillion won, is pursuing an initial public offering (IPO) with FOG-001, a targeted drug for ‘untreatable’ cancer. FOG-001 is a peptide drug that inhibits the interaction between β-catenin and TCF transcription factors; in early studies, it reduce
2026-05-21
Bristol Myers Squibb (BMS) has joined the big pharma AI race by introducing Anthropic’s AI model Claude into drug development. Claude will be used in regulatory submission processes, including supporting the preparation of clinical reports, and to uncover the value of data accumu
2026-05-21
Bristol Myers Squibb (BMS) will deploy the AI platform Claude companywide for use by more than 30,000 employees. The company aims to reduce the time required to identify drug candidates by 50% and increase clinical productivity by more than 35%. BMS plans to integrate fragmented
2026-05-21
The world’s first high-resolution “olfactory map” identifying the locations and functions of olfactory receptors inside the nose has been completed and published in the journal Cell. The map deciphers the olfactory code that distinguishes millions of smells, showing which recepto
2026-05-21
A study reporting the successful reversal of the Friedreich ataxia (FRDA) phenotype in human cerebellar organoids has been published in the international journal Communications Biology. The researchers corrected neurodevelopmental defects by transplanting “navigation glia” into c
2026-05-21
A research team at Chongqing Medical University in China developed a new nanoplatform to treat intestinal ischemia-reperfusion injury, achieving antioxidant, anti-inflammatory and regenerative effects simultaneously. The nanoplatform efficiently delivers drugs to damaged intestin
2026-05-21
U.S. biotech company Urza Bio has raised $30 million (approximately 43.5 billion won) in a Series A financing and plans to develop a treatment for idiopathic pulmonary fibrosis (IPF). The company’s lead pipeline, ORJ-001, is a peptide drug licensed from South Korean company NIBEC
2026-05-21
Nabix’s investigational drug candidate for idiopathic pulmonary fibrosis (IPF) has been licensed to U.S.-based Orza Bio in a deal valued at 630 billion won ($435 million). The compound activates beta-integrin receptors, which are essential for maintaining lung structure, and Orza
2026-05-21
Incyte paid Genesis $120 million (approximately 174 billion won) and expanded its AI drug discovery partnership. The companies will jointly research at least five new targets, with the total deal value exceeding $1 billion (approximately 1.45 trillion won). Incyte also secured op
2026-05-21
